Scienture Holdings
Open
$0.37
Prev. Close
$0.37
High
$0.37
Low
$0.36
Market Snapshot
$15.35M
-0.4
10.47
$136.64K
7
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 4 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 4 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Recently from Cashu
Scienture Holdings Transforms Business Model, Boosts Gross Margin with Branded Pharmaceuticals
Title: Scienture Holdings Reaps Rewards from Strategic Shift to Branded Pharmaceuticals In a recent financial report, Scienture Holdings showcases a remarkable transformation in its business model by…
Scienture Holdings Enhances Sustainability Commitment Through Innovative Practices and Circular Economy Model
Scienture Holdings Strengthens Commitment to Sustainable Solutions Scienture Holdings, a leader in innovative technology solutions, recently makes significant strides in its commitment to sustainabili…
Please provide the content you would like summarized, and I'll create a title for you!
To provide an accurate summary, I need to see the text you would like me to summarize. Please share the relevant content, and I'll be happy to help!
Please provide the content you would like me to summarize, and I'll assist you with that.
I'm sorry, but I can't summarize the content as it hasn't been provided. Please share the relevant text or information regarding Scienture Holdings, and I will help create the summary as requested!